Morepen Laboratories has launched Desloratadine Tablets USP, 5 mg, in the United States, its first prescription generic in that market. In an exchange filing on Monday, 9 November 2026, the drugmaker said the product would be sold in 100-count and 500-count packs through Morepen Bio Inc., its wholly owned US subsidiary.
The launch is small in revenue terms and large in strategy. Morepen has supplied desloratadine, the active ingredient, to American customers for years. Selling the finished tablet and distributing it locally moves the company down the value chain from bulk chemistry into a business where the buyer is a pharmacy chain or wholesaler.
Read more on newzshort:
Maharashtra FDA Suspends 43 More Food Licences
Why The First Prescription Launch Matters
That step changes the arithmetic of a molecule. An API supplier earns a conversion margin on kilograms of powder, exposed to spot pricing and to a handful of large buyers. A finished-dosage supplier sells boxes, holds the ANDA, and captures the formulation, packaging and distribution margin too. Because Morepen already makes the desloratadine it will press into tablets, it starts with an input cost advantage that most generic marketers do not have.
The molecule is not a soft target. Desloratadine is an off-patent antihistamine with many approved generic competitors in the US, and generic prices there have fallen for years. A first product rarely earns much on its own. It is the proof that lets distributors take the next ten filings seriously.
Read more on newzshort:
Hindalco Q2 Profit At Record Rs 7,532 Crore
The Numbers Behind The Move
The launch lands on the strongest set of quarterly numbers in Morepen’s recent history. For the quarter ended September 2026, revenue rose 81 per cent year on year to Rs 746.50 crore and net profit more than doubled to Rs 88.89 crore, a rise of 116.59 per cent, according to results published on 27 October. EBITDA margin expanded to 16.5 per cent from 7.5 per cent a year earlier, pointing to a richer mix of contract manufacturing and export revenue rather than a one-off gain.
The stock reacted before the filing was widely read. Shares rose about 5 per cent on Monday, snapping an eight-day losing streak, CNBC-TV18 reported. At Rs 99 the company is valued at roughly Rs 5,425 crore, about 31 times trailing earnings, on a return on equity of 5.34 per cent. That is not a valuation for one antihistamine tablet. It is a valuation for the transition.
From API Supplier To Dosage Maker
Morepen has spent four decades in API chemistry, building regulated-market manufacturing and a customer list that includes formulators in the US and Europe. The move into finished doses has been running for over a year: the company announced an Rs 825 crore multi-year global CDMO contract in February 2026 and reported its highest ever first-quarter profit in the June 2026 quarter.
The sequence is deliberate. Morepen first sold over-the-counter products in the US, then filed its first ANDA, for sitagliptin phosphate tablets in 25 mg, 50 mg and 100 mg strengths, in September 2026. That application is still under review at the US Food and Drug Administration. Monday’s launch is the commercial step that goes with it, and the company says it will pursue more prescription filings while evaluating high-potency APIs and oncology. The platform, from API chemistry to drug product development, is laid out by Morepen on its own site.
The Risks That Come With The Pivot
Three risks sit under the story. US generic prices keep eroding, so a late entrant on a mature molecule can find its only durable margin is the one it saves by making its own ingredient. Regulated-market manufacturing depends on inspections, and one adverse observation at a plant can delay filings for quarters. A first ANDA approval also arrives in a market where distributors decide how much shelf space a new label gets.
One overhang cleared in October, when the Himachal Pradesh High Court quashed a Rs 117.94 crore GST demand against the company. That removes a contingent liability at the same time as the export business scales, and it is the kind of item that rarely appears in a product announcement.
What To Watch
The editorial read is that the market has already priced the transition and is now waiting for evidence. Three markers matter more than Monday’s headline. The sitagliptin ANDA decision will show whether the regulatory pipeline is real. The share of revenue coming from CDMO contracts will show whether the Rs 825 crore order is a base or a spike. And the 16.5 per cent margin will show whether the mix shift holds once the current export cycle turns. The first prescription generic is a statement of intent. The money will be made, or lost, in the filings that follow it.
